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ABSTRACT
Androgen receptor (AR) signalling and the PI3K pathway mediate survival signals 
in prostate cancer, and have been shown to regulate each other by reciprocal negative 
feedback, such that inhibition of one activates the other. Understanding the reciprocal 
regulation of these pathways is important for disease management as tumour cells 
can adapt and survive when either single pathway is inhibited pharmacologically. 
We recently carried out genome-wide exon-specific profiling of prostate cancer cells 
to identify novel androgen-regulated transcriptional events. Here we interrogated 
this dataset for novel androgen-regulated genes associated with the PI3K pathway. 
We find that the PI3K regulatory subunits PIK3R1 (p85ɑ) and PIK3R3 (p55ʏ) are 
direct targets of the AR which are rapidly repressed by androgens in LNCaP cells. 
Further characterisation revealed that the PIK3CA p110ɑ catalytic subunit is also 
indirectly regulated by androgens at the protein level. We show that PIK3R1 mRNA 
is significantly under-expressed in prostate cancer (PCa) tissue, and provide data 
to suggest a context-dependent regulatory mechanism whereby repression of the 
p85ɑ protein by the AR results in destabilisation of the PI3K p110ɑ catalytic subunit 
and downstream PI3K pathway inhibition that functionally affects the properties of 
prostate cancer cells.  
INTRODUCTION
Prostate cancer (PCa), the most commonly-
diagnosed malignancy in males [1], is characterised by 
its dependence on androgen receptor (AR) signalling. 
The initial treatment standard for patients with locally 
advanced or metastatic PCa is androgen deprivation 
therapy (ADT). This usually inactivates the AR, but after 
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2-3 years many patients develop castrate resistant PCa 
(CRPCa) where despite low serum testosterone levels AR 
signalling persists [2]. Progression to CRPCa may be the 
result of reactivation of AR signalling or reprogramming 
of the AR transcriptional landscape and has limited 
treatment options[3-5]. 
The phosphatidylinositol 3-kinase (PI3K) pathway 
is a key oncogenic signalling pathway in prostate cancer 
and has been shown to be altered in 42% of primary and 
up to 49% of metastatic cases[6, 7]. PIK3 signalling 
has a diverse array of functions including the regulation 
of cell survival, growth, proliferation, metabolism 
and angiogenesis [8]. The PI3K enzyme is an obligate 
heterodimer composed of a catalytic subunit (p110ɑ) 
and one of a number of regulatory subunits [27]; the 
most common of which is derived from the p85ɑ gene 
(PIK3R1). Recently, reciprocal cross-talk between AR 
signalling and the PI3K pathway has been highlighted as 
a potential mechanism underlying CRPCa. AR signalling 
and the PI3K pathway have been shown to regulate each 
other by reciprocal negative feedback, such that inhibition 
of one pathway activates the other[9]. As both pathways 
mediate survival signals in prostate cancer tumour cells 
can adapt and survive when either single pathway is 
inhibited pharmacologically. Understanding the reciprocal 
regulation of these pathways is of critical importance in 
terms of disease management.
We recently carried out a global analysis of the 
PCa transcriptome to identify novel androgen-regulated 
transcriptional events[10-12]. In the light of evidence 
implicating cross-talk with the AR, we searched this 
dataset for novel androgen-regulated genes associated with 
PI3K signalling. Our data identifies a direct transcriptional 
link between the androgen receptor and PIK3 signalling 
pathways. We find that the PIK3R1 gene is directly 
repressed by androgens and has decreased expression 
in clinical prostate cancer. Our data suggests a context-
dependent regulatory mechanism whereby AR-mediated 
repression of the p85ɑ protein results in destabilisation of 
the PI3K p110ɑ catalytic subunit and downstream PI3K 
pathway inhibition. 
RESULTS
The PI3K regulatory subunit genes PIK3R1 and 
PIK3R3 are direct targets of the AR
Complete gene lists from our ExonArray dataset 
[10] were correlated with previously published mRNA 
expression data from 218 prostate tumours [6] with the 
aim of identifying novel androgen-regulated genes with 
roles in PI3K signalling. This highlighted two androgen-
regulated subunits of PI3K encoded for by the PIK3R1 
and PIK3R3 genes which were identified by Taylor et al. 
(2010) as being inactivated in 58% and 16% of metastatic 
prostate cancer tumours respectively [6] (Figure 1). Full 
gene lists were then uploaded to the web-based Ingenuity 
Pathway Analysis (IPA) software programme, and the IPA 
‘Core Analysis’ function was used to identify additional 
androgen-regulated genes within pathways associated with 
PIK3R1 and PIK3R3 (Supplementary Figures 1 & 2). This 
identified an additional 34 genes which were validated 
as androgen-regulated in LNCaP cells by real-time 
PCR (Supplementary Table 1). The genomic loci of AR 
binding sites mapped by ChIP in LNCaP cells [13] were 
uploaded onto the UCSC genome browser. Two known 
AR binding sites within 100 kb of the PIK3R1 gene and 
four AR binding sites within 50 kb of the PIK3R3 gene 
were identified (Supplementary Table 2). 
To test whether the PIK3R1 and PIK3R3 genes 
might be under direct control of androgens through AR 
regulation, we examined PIK3R1 and PIK3R3 expression 
in LNCaP cells grown in steroid deplete medium and cells 
treated with 10nM of the synthetic androgen analogue 
R1881 for 24 hours by real-time PCR. The PIK3CA gene 
which codes for the p110ɑ catalytic subunit of PI3K was 
also studied. PIK3R1 and PIK3R3 mRNA expression 
were significantly reduced within 9 hours of treatment 
with 10nM R1881 (p<0.015), whereas there was no 
significant change in PIK3CA expression (Figure 2A,B). 
Repression of the PIK3R1 and PIK3R3 genes was also 
observed with a range of R1881 concentrations from 
1nM to 100nM (p<0.01) consistent with this happening 
under physiological conditions within the prostate (Figure 
2C). To test whether androgen-mediated suppression of 
PIK3R1 and PIK3R3 is a direct result of AR activity, we 
Figure 1: Expression of PIK3R1, PIK3R3 and PIK3CA 
mRNA in 218 prostate cancer clinical samples 
as measured by Taylor et al. [6]. PIK3R1 mRNA is 
downregulated in 22% of primary and 58% of metastatic prostate 
cancer tissue samples (relative to normal prostate tissue).
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treated LNCaP cells with 10nM R1881 in the presence 
and absence of cycloheximide to inhibit de novo protein 
synthesis. Androgen mediated down-regulation of PIK3R1 
and PIK3R3 was still observed in the presence of the 
protein synthesis inhibitor cycloheximide (p<0.04). Again, 
addition of cycloheximide had no effect on the expression 
of PIK3CA mRNA. The observation that PIK3R1 and 
PIK3R3 repression is not affected by inhibition of de novo 
protein synthesis indicates that this is likely to be directly 
mediated by the AR (Figure 2D). Although unlikely, it 
is still also possible that the regulation of PIK3R1 and 
PIK3R3 by androgens is mediated by an intermediate 
protein with a long half-life (which is the case for the AR).
Figure 2: The PI3K regulatory subunit genes PIK3R1 and PIK3R3 are direct targets of the AR. (A) LNCaP cells were 
cultured in medium supplemented with 10% dextran charcoal stripped FBS to produce a steroid deplete medium (SD). Following culture 
for 72 hours, cells were treated with 10 nM synthetic androgen analogue methyltrienolone (R1881) for 24 hours (A+). Relative expression 
of PIK3R1, PIK3R3 and PIK3CA was detected by real-time PCR (B) Expression of PIK3R1, PIK3R3 and PIK3CA mRNA in cells grown 
in steroid deplete (SD) or androgen (A+) treated conditions over a 24 hours period. The response to androgens was confirmed using PSA 
(KLK3) expression (not shown). (C) Repression of PIK3R1 and PIK3R3 is also evident in LNCaP cells treated with 0.1 to 100 nM of 
R1881. (D) The reduction in PIK3R1 and PIK3R3 mRNA expression in response to androgens is still seen in the presence of 1 μg/ml 
cycloheximide (CHX) as confirmed by real-time PCR.
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The p85ɑ, p55ʏ and p110ɑ proteins are repressed 
by androgens
The above data shows that the p85ɑ PI3K 
regulatory subunit gene PIK3R1 and the p55ʏ subunit 
gene PIK3R3 are direct transcriptional targets of the AR, 
whereas expression of the p110ɑ PI3K catalytic subunit 
PIK3CA gene does not change with androgens. We next 
examined parallel expression of the p110ɑ, p85ɑ and 
p55ʏ proteins in LNCaP cells using western blotting 
and immunofluorescence. The expression of the p85ɑ 
and p55ʏ proteins was repressed by treatment of 10nM 
R1881 for either 24 or 48 hours. Although we did not 
see any change in expression at the transcript level of the 
PIK3CA gene in response to androgens in LNCaP cells, 
at the protein level p110ɑ was strongly repressed after 
treatment with androgens (Figure 3A,B). Confirming this 
effect on protein levels was mediated by the AR, we found 
that androgen-mediated repression of the p85ɑ, p55ʏ 
and p110ɑ proteins is prevented when cells are depleted 
of the AR using esiRNA (Figure 3C). The specificity 
of the antibodies used was confirmed by detection 
of over-expressed protein and detection of esiRNA 
mediated protein depletion (Figure 4A & Supplementary 
Figures 3A,B). Taken together, these results indicate 
that while the PI3K regulatory subunits p85ɑ and p55ʏ 
are direct targets of the AR which are rapidly repressed 
by androgens, repression of the PI3K catalytic subunit 
p110ɑ by androgens operates at the protein level only. 
Consistent with this pattern of repression of the PIK3 
pathway, as observed previously [14] treatment of LNCaP 
cells with androgens also reduced expression levels of 
phosphorylated AKT (pAKT). 
The p110ɑ PI3K catalytic subunit is stabilised by 
p85ɑ
The above data predicted that AR-regulated 
suppression of p85ɑ, p55ʏ and p110ɑ in PCa cells may 
modulate PI3K signalling in response to androgens. To 
test this prediction, we depleted p85ɑ and p55ʏ using 
esiRNA and examined the downstream effects on PI3K 
signalling in LNCaP cells. The p85ɑ regulatory subunit 
has previously been shown to regulate and stabilise the 
PIK3CA p110ɑ catalytic protein [15-17] 35]. Consistent 
with this, knockdown of p85ɑ caused a reduction in p110ɑ 
protein levels (Figure 4A). This result was confirmed by 
over-expression of p85ɑ in HEK293 cells (which increased 
the level of p110ɑ) (Supplementary Figure 3A). These 
findings support the repression of p110ɑ by androgens 
being mediated by a mechanism involving reduction of its 
protein partner p85ɑ (which is a direct target of the AR). 
In contrast, both depletion of p55ʏ by esiRNA in LNCaP 
cells, and over-expression of p55ʏ in HEK293 cells had no 
significant effect on p110ɑ protein levels (Supplementary 
Figure 3A.B). 
Figure 3: The p85ɑ, p55ʏ and p110ɑ proteins are repressed by androgens. (A) Expression of  p85ɑ, p55ʏ and p110ɑ protein 
is reduced in LNCaP cells treated with 10 nM R1881 for 24 and 48 hours as detected by western blot. Actin was used as a loading control. 
(B) Immunofluorescent staining of LNCaP cells grown in steroid depleted conditions indicates that  p85ɑ, p55ʏ and p110ɑ are localised 
to the cytoplasm. Bar is 10 μM. (C) Depletion of AR protein in LNCaP cells by esiRNA shows that when the AR is depleted there is no 
reduction in p85ɑ, p55ʏ or p110ɑ protein in response to androgens. The specificity of the antibodies used was confirmed by detection of 
over-expressed protein and esiRNA mediated protein depletion (Supplementary Figure 3).
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Depletion of p85ɑ reduces pAKT in LNCaP cells 
and decreases cell proliferation
We next examined phosphorylation of the serine 
kinase AKT (pAKT) as an indicator of endogenous PI3K 
activity [18]. Depletion of p85ɑ in LNCaP cells reduced 
levels of pAKT (actin and total AKT levels were used as 
loading controls). In contrast, depletion of p55ʏ had no 
effect on pAKT. These results suggest that in LNCaP cells 
the depletion of p85ɑ but not p55ʏ reduces PI3K activity 
(Figure 4A and Supplementary Figure 3B). Activated 
AKT kinase modulates the function of numerous 
substrates involved in cell cycle progression [19, 20], and 
we observed that depletion of p85ɑ in LNCaP cells led 
to reduced levels of cyclinD mRNA and protein (Figure 
4A). Consistent with these changes, cell cycle analysis of 
PIK3R1 depleted cells indicated a significant reduction 
in the proportion of cells in S phase (p<0.01) and an 
increase in G0/G1 (P<0.02) (Figure 4B). We also observed 
significantly reduced cell growth after treatment with 
PIK3R1 esiRNA (p>0.03) (Figure 4C). Taken together 
our results suggest that depletion of p85ɑ in LNCaP 
cells results in downstream PI3K pathway inhibition that 
can functionally affect the properties of prostate cancer 
cells. As depletion of PIK3R1 by esiRNA in LNCaP cells 
reduced expression of CCND1 mRNA we tested whether 
patients with reduced PIK3R1 also have reduced cyclin 
D expression. Consistent with this, re-analysis of the 
data generated by Taylor et al. [6] indicated a significant 
tendency towards co-occurance (p<0.007) for both down-
regulation of PIK3R1 and cyclin D (Figure 4D).
PIK3R1 is under-expressed in PCa
We carried out a further meta-analysis of 747 
prostate cancer tumours using data from 10 previously 
published studies[6, 21-29]. Analysis of PIK3R1, PIK3R3 
and PIK3CA mRNA expression in these datasets revealed 
that PIK3R1 was significantly down-regulated in PCa 
tumours relative to normal tissue in 9 of the 10 studies. 
PIK3R3 and PIK3CA were significantly altered in 3/10 
studies and 1/10 respectively (Supplementary Table 3). 
Analysis of the 122 samples studied by Grasso et al. 
[23] identified PIK3R1 as -1.428 fold under-expressed 
Figure 4: Depletion of p85ɑ reduces pAKT in LNCaP cells and decreases cell proliferation. (A) Depletion of PIK3R1 / 
p85ɑ in LNCaP cells by esiRNA was confirmed by western blotting (left panel) and by real-time PCR (right panel). Loss of p85ɑ caused a 
reduction in the relative levels of p110ɑ, pAKT (total AKT and actin were used as loading controls), and cyclin D. (B) Cell cycle analysis 
of LNCaP cells treated with PIK3R1 esiRNA for 72 hours. (C) Relative cell number counts for LNCaP cells treated with PIK3R1 esiRNA 
for 72 or 96 hours. (D) Analysis of data generated by Taylor et al. [6] for co-occurrence of PIK3R1 and CCND1 mRNA under-expression.
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in prostate carcinoma relative to normal prostate tissue 
(p=4.99E-5) and placed PIK3R1 in the top 10% of 
under-expressed genes (Figure 5A). Similarly, analysis 
of 101 samples studied by Tomlins et al. [21] found 
that expression of PIK3R1 was reduced by -3.266 fold 
(p=5.87E-7) in prostate carcinoma relative to normal 
tissue, and in this dataset PIK3R1 was in the top 1% of 
under-expressed genes (Figure 5B) (data was generated 
using Oncomine [30]). Interrogation of previously 
published data [6] also showed reduced survival in 
patients where the PIK3R1 gene is altered (median months 
disease free is reduced from 110 to 65 (p<0.005) (Figure 
5C). We also analysed expression of PIK3R1 mRNA 
in 9 prostate tumour tissue samples relative to matched 
normal tissue from the same patient. PIK3R1 expression 
was significantly reduced in 6/9 prostate tumour tissue 
samples when compared with matched normal tissue 
from the same patient (Figure 5D). Analysis of PIK3R3 
Figure 5: PIK3R1 is under-expressed in PCa. Expression of PIK3R1 in clinical PCa samples measured by (A) Grasso et al. [23] 
and (B) Tomlins et al. [21]. In both studies the expression of PIK3R1 mRNA is significantly reduced in prostate carcinoma relative to 
normal prostate gland tissue. Data was generated using Oncomine [30]. (C) Interrogation of previously published data [6] also showed a 
reduced rate of survival in patients which have an alteration in the PIK3R1 gene. (D) Real-time PCR analysis of PIK3R1 mRNA expression 
in matched normal and tumour tissue from 9 PCa patients. Expression of PIK3R1 was significantly reduced in tumour relative to normal 
tissue in 6 out of the 9 patients studied (p<0.05). (E) Analysis of PIK3R1 mRNA in previously published RNA-sequencing data [33] from 
7 prostate cancer patients before and after androgen ablation therapy. PIK3R1 expression is increased in 5/7 patients following the removal 
of androgens (measured by log2 fold change of RNA-Seq reads detected).
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and PIK3CA expression in the same sample sets indicated 
no significant differences (Supplementary Figure 4). The 
above data indicates that PIK3R1 expression is repressed 
by the androgen receptor in LNCaP cells in response to 
androgens. In order to see if reciprocal changes might 
occur in patients before and after androgen deprivation 
therapy we analysed previously published RNA-
Sequencing data from 7 PCa patients [13]. In 5/7 patients 
expression of PIK3R1 was increased after androgens were 
depleted (Figure 5E) consistent with the change in PIK3R1 
expression in response to androgens being increased in 
patients in response to anti-androgen treatment. Taken 
together, these results indicate that PIK3R1 is under-
expressed in PCa. 
DISCUSSION
Here we show that expression of the PI3K 
regulatory subunit p85α protein-encoding gene PIK3R1 
is under direct control of androgens and is reduced in 
prostate carcinoma tissue relative to the normal prostate 
gland. Our data identifies a direct transcriptional link 
between the androgen receptor and PI3K signalling 
pathways and suggests a context-dependent regulatory 
mechanism whereby repression of the p85α protein by the 
AR results in destabilisation of the PI3K p110α catalytic 
subunit and downstream PI3K pathway inhibition (Figure 
6). A reciprocal regulation between PI3K and AR and 
signalling pathways has been previously implicated 
in prostate tumorigenesis [7][14, 33]. As tumour cells 
can adapt and survive when either single pathway is 
inhibited pharmacologically, understanding the reciprocal 
regulation of these pathways further is crucial for disease 
management [31]. Carver et al. [7] showed that PI3K 
signalling inhibits AR signalling via feedback inhibition 
of human epidermal growth factor 2/3 (HER2/3), and 
that AR signalling down-regulates PI3K signalling 
through FK506-binding protein-5 (FKBP-5) mediated 
stabilisation of the AKT phosphatase PHLPP [7]. The new 
data reported here thus indicate that these two pathways 
are even more closely linked at the level of transcriptional 
control. 
PIK3R1 under-expression has previously been 
shown to be an independent prognostic marker in breast 
cancer [29] and low PIK3R1 expression has been linked to 
high grade lung cancer [30]. Liver specific loss of PIK3R1 
in a murine model results in the development of aggressive 
hepatocellular cancer [13], and loss of PIK3R1 mRNA in 
the MCF-7 breast cancer cell line is associated with a more 
invasive phenotype [32]. Studies have also suggested that 
PIK3R1 expression negatively influences glioblastoma 
tumour growth and patient survival [33]. The role of p85α 
in the PI3K pathway is complex. In contrast to the studies 
discussed above, PIK3R1 has also been implicated as an 
oncogene in endometrial, ovarian and colon tumours [28] 
[16]. Previous studies have shown that optimal signalling 
through the PIK3 pathway depends on a critical molecular 
balance between the regulatory and catalytic subunits; 
haploinsufficiency of PIK3R1 can result in PI3K pathway 
activation, whereas homozygous depletion inhibits the 
pathway [22][31, 34]. Point mutations in and deletions 
of the PIK3R1 gene have been reported in up to 20% of 
endometrial cancer cases and in 2.2% of breast cancers 
[16, 36] [29]. Analysis of organoid cultures derived from 
patients with advanced prostate cancer detected mutations 
in PIK3R1 in 2/7 patients [30]. Taylor et al. [6] did not 
identify any PIK3R1 mutations in their study of 218 PCa 
tumours. However, a recent study by Robinson et al. [7] 
identified PIK3R1 mutations and deletions in 4.7% and 
1.3% of metastatic CRPCa respectively. Together with our 
data this shows that down-regulation of PIK3R1 mRNA/
p85α is more common in prostate tumours than mutation 
of the gene, and the effect of p85α on the PI3K pathway 
and tumour development is likely to be tissue and context-
dependent and determined by the relative activities of 
p110α, p85α and PTEN.
Our work demonstrates a direct transcriptional link 
between AR signalling and the PI3K pathway mediated 
by AR-dependent repression of PIK3R1. Recent work has 
demonstrated a dynamic interplay between PI3K and AR 
Figure 6: Model: AR-mediated repression of the p85ɑ 
protein results in destabilisation of the PI3K p110ɑ 
catalytic subunit and downstream PI3K pathway 
inhibition. Androgen receptor (AR) signalling and the PI3K 
pathway have been shown to regulate each other by reciprocal 
negative feedback in PTEN negative cells. We show that the 
PI3K regulatory subunit PIK3R1 (p85ɑ) is a direct target of 
the AR which is rapidly repressed by androgens in prostate 
cancer cells. The data presented suggests a context-dependent 
regulatory mechanism whereby repression of the p85ɑ protein 
by the AR results in destabilisation of the PI3K p110ɑ catalytic 
subunit downstream PI3K pathway inhibition.
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signalling in resistance to ADT [31, 32]. Activation of 
PI3K signalling as a result of treatments targeting the AR 
may therefore enable prostate cancer cells to survive and 
proliferate without androgens. This concept is underlined 
by the finding that androgen inhibition actually accelerates 
progression to invasive PCa in PTEN-deficient mice 
[34]. These findings and the work described in this study 
support a route involving combinatorial inhibition of AR 




Gene lists from Rajan et al. [10] were uploaded 
to the web-based Ingenuity Pathway Analysis (IPA; 
Ingenuity Systems) software programme, and the “Core 
Analysis” function was used to study direct and indirect 
regulatory relationships between genes and their known 
biological functions.
Antibodies
The following antibodies were used in the study: 
p85ɑ mouse antibody (Abcam, ab22653), anti p55ʏ rabbit 
antibody (Sigma, HPA005751), p110ɑ rabbit antibody 
(Cell Signalling, 4249), Total AKT rabbit antibody (Santa 
Cruz, sc-8312), anti-phospho-AKT1 (pSer473) rabbit 
antibody (Sigma, SAB4300042), anti-Cyclin D1 (Abcam 
ab21699), anti-AR mouse antibody (BD Bioscience, 
554226), anti-FLAG mouse monoclonal (F3165, Sigma), 
normal rabbit IgG (711-035-152 Jackson labs) and normal 
mouse IgG (715-036-150 Jackson labs).
RT-qPCR
Cells were harvested and total RNA extracted 
using TRI-reagent (Invitrogen, 15596-026), according to 
the manufacturer’s instructions. RNA was treated with 
DNase 1 (Ambion) and cDNA was generated by reverse 
transcription of 500ng of total RNA using the Superscript 
VILO cDNA synthesis kit (Invitrogen, 11754-050). 
Quantitative PCR (qPCR) was performed in triplicate on 
cDNA using SYBR® Green PCR Master Mix (Invitrogen, 
4309155) using the QuantStudio™ 7 Flex Real-Time PCR 
System (Life Technologies). Samples were normalised 
using the average of three reference genes: GAPDH, 
β –tubulin and actin. All primer sequences are listed in 
Supplementary Table 4.
DNA constructs
For creation of the Flp-In™-293 stable cell line 
PIK3R1 and PIK3CA and were cloned into pCDNA5 using 
BamH1 and Not1. PIK3R3 was cloned into pCDNA5 
using Not1 and Xho1.
Cell culture
Cell culture and androgen treatment of cells was 
as described previously [10-12]. All cells were grown 
at 37°C in 5% CO2. LNCaP cells (CRL-1740, ATCC) 
were maintained in RPMI-1640 with L-Glutamine 
(PAA Laboratories, R15-802) supplemented with 10% 
Fetal Bovine Serum (FBS) (PAA Laboratories, A15-
101). For androgen treatment of LNCaP cells, medium 
was supplemented with 10% dextran charcoal stripped 
FBS (PAA Laboratories, A15-119) to produce a steroid-
deplete medium. Following culture for 72 hours, 10nM 
synthetic androgen analogue methyltrienolone (R1881) 
(Perkin–Elmer, NLP005005MG) was added (Androgen 
+) or absent (Steroid deplete) for the times indicated. 
Where indicated, LNCaP cells were pre-treated for 1 
hour with vehicle (dimethylsulfoxide; DMSO) (Sigma, 
C1988) or 1 μg/ml cycloheximide (Sigma, D2438) prior 
to addition of 10 nM R1881 for 24 hours as previously 
described [16]. Flp-In™-293 cells (R750-07, Invitrogen) 
were maintained in DMEM GlutaMax (Invitrogen, 10566-
040), supplemented with 10% FBS (PAA Laboratories, 
A15-101) and stable cell lines generated using the Flp-
In T-Rex Core Kit (K6500-01, Invitrogen) according to 
the manufacturer’s instructions. Protein expression was 
induced using 1 μg/ml tetracycline (T7660, Sigma) for 72 
hours.
esiRNA
esiRNAs PIK3R1 and PIK3R3 were obtained from 
Sigma-Aldrich (EHU151811 and EHU123491). 
Cell cycle analysis
Cell cycle analysis was carried out using the TaliR 
Cell Cycle Kit (Life Technologies A10798) and the TaliR 
Image-based Cytometer. The data was then analysed 
using ModFit. Relative cell numbers following esiRNA 
treatment were determined using the TaliR Image-based 
Cytometer (Life Technologies).
Clinical samples
Our study made use of RNA from 32 benign samples 
from patients with benign prostatic hyperplasia (BPH) and 
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17 malignant samples from transurethral resection of the 
prostate (TURP) samples. Malignant status and Gleason 
score were obtained for these patients by histological 
analysis. We also analysed normal and matched PCa 
tissue from 9 patients obtained by radical prostectomy. 
The samples were obtained with ethical approval through 
the Exeter NIHR Clinical Research Facility tissue bank 
(Ref: STB20). Written informed consent for the use of 
surgically obtained tissue was provided by all patients.
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